Please login to the form below

Not currently logged in
Email:
Password:

WuXi PharmaTech potential USD 184.7m IPO

China-headquartered pharmaceutical and biotech company WuXi PharmaTech has released its initial public offering of 13,188,979 American Depositary Shares

China-headquartered pharmaceutical and biotech company WuXi PharmaTech (WuXi) has released its initial public offering (IPO) of 13,188,979 American Depositary Shares (ADSs).

Of the 13,188,979 ADSs sold in the offering, 10,000,000 ADSs were sold by WuXi, while 3,188,979 ADSs were sold by selling shareholders. The company has granted the underwriters a 30-day option to purchase up to an additional 1,978,347 ADSs to cover over-allotments.

WuXi says it should raise USD 107.8m from the sale, or USD 129.9m if underwriters exercise their options. The firm plans to use USD 40m to expand its Jingsu facility, USD 40m to build a new centre in Suzhou and the rest for general corporate purposes.

Each ADS represents eight ordinary shares and was priced at USD 14.00 per ADS. The ADSs will begin trading on the New York Stock Exchange on 9 August 2007 under the symbol 'WX.'

Credit Suisse Securities and J P Morgan Securities acted as representatives of the underwriters and joint book runners, while Jefferies & Company acted as co-manager for the offering.

WuXiís net revenue for Q1 FY07 rose 165 per cent on Q1 FY06 figures to rest at USD 33.8m. Net income was USD 6m, excluding pre-IPO stock compensation.

9th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics